TrivarX Limited (TRI.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 0 | 0 | 0 | 0 | - | 0 | - |
| Operating profit | AUD m | -2 | -2 | ||||||
| Net profit | AUD m | -1 | -13 | -3 | -1 | -1 | - | -2 | - |
| EPS reported | AUD | -0.00 | -0.00 | ||||||
| Operating cashflow per share | AUD | -0.00 | -0.00 | ||||||
| Capex per share | AUD | 0.00 | 0.00 | ||||||
| FCF per share | AUD | -0.00 | -0.00 | ||||||
| Free cash flow | AUD m | -0 | -1 | ||||||
| Net debt | AUD m | -1 | -3 | ||||||
| Book value equity | AUD m | 13 | 24 | ||||||
| Book value per share | AUD | 0.03 | 0.03 | ||||||
| Number of shares | m | 494.8 | 683.52 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.55 | 0.44 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -37.01 | -9.68 | ||||||
| EV/EBITDA LTM | x | -3.28 | -4.53 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -9.08% | -20.58% | ||||||
| FCF Yield | % | -2.70% | -10.33% | ||||||
| Quality | |||||||||
| ROE | % | -7.45% | -11.66% | ||||||
| ROIC | % | -7.60% | -8.85% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.12 | -7.21 | ||||||
| Net Debt/EBITDA | x | 0.57 | 1.61 | ||||||
| EBIT/Net interest | x | -60.62 | -132.83 | ||||||
| Net debt/market cap | % | +0.33% | +0.10% | ||||||
| Net debt/Equity | x | -0.10 | -0.14 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presence extends across Australia and the United States. The company delivers mental well-being provisions tailored for corporate clients through its enterprise health offerings, concurrently developing solutions for medical service providers. Established in 1987, the entity was formerly known as Medibio Limited until its rebranding as TrivarX Limited in October 2023. Its principal place of business is situated in Mount Lawley, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presence extends across Australia and the United States. The company delivers mental well-being provisions tailored for corporate clients through its enterprise health offerings, concurrently developing solutions for medical service providers. Established in 1987, the entity was formerly known as Medibio Limited until its rebranding as TrivarX Limited in October 2023. Its principal place of business is situated in Mount Lawley, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free